

6th October 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I am researching the incidence and treatment of breast cancer. I would greatly appreciate if you could answer the following questions

- 1) How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

• Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	49
• Abemaciclib + Fulvestrant	0
• Alpelisib + Fulvestrant	1
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only	0
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel	0
• Atezolizumab	1
• Capivasertib	3
• Capecitabine as a single agent	38
• Carboplatin + Paclitaxel	8
• Elacestrant	7
• Eribulin as a single agent or in combination	3
• Everolimus + Exemestane	1
• Fulvestrant as a single agent	0
• Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	25
• Palbociclib + Fulvestrant	6
• Parp Inhibitors (Olaparib/Talazoparib)	3
• Pembrolizumab Monotherapy	3

• Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	0
• Carboplatin + Paclitaxel + Pembrolizumab	11
• Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	1
• Phesgo (Pertuzumab + Trastuzumab in a single injection)	45
• Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	97
• Ribociclib + Fulvestrant	30
• Sacituzumab Govitecan	3
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	24
• Trastuzumab deruxtecan (Enhertu)	4
• Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	34
• Trastuzumab emtansine (Kadcyla)	7
• Any other active systemic anti-cancer therapy	70
• Pembrolizumab subcutaneous injection	6

- 2) In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	45	0	45
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	1	0	1
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	34	12	22
Trastuzumab deruxtecan (Enhertu)	4	1	3
Trastuzumab emtansine (Kadcyla)	7	0	7
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	49	42	7
Abemaciclib + Fulvestrant	0	0	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	97	37	60
Ribociclib + Fulvestrant	30	1	29
Capecitabine as a single agent	38	1	37
Carboplatin + Paclitaxel	8	8	0
Carboplatin + Paclitaxel + Pembrolizumab	11	0	11

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm